Healthcare Economics Engine

Biosimilar Adoption Modeling

Forecast biosimilar uptake rates, model formulary tier changes, and quantify multi-year savings from switching brand biologics to biosimilar alternatives

The Biosimilar Opportunity Gap

Biosimilars launched 5 years ago. They cost 30-60% less than brand biologics. But your utilization? Still under 15%. Why? Because your PBM and specialty pharmacy make more money on the brand. Nobody's incentivized to switch your members. You're leaving millions on the table.

Biosimilar Discount

30-60%

vs. brand biologics

Current Adoption

8-18%

typical plan utilization

Target Adoption

60-80%

clinically appropriate

✗ What Fails Without This Engine

•Can't model savings: don't know how many members are biosimilar-eligible
•No adoption curve: assume instant 100% conversion (never happens)
•Physician resistance unquantified—no plan to overcome clinical inertia
•Rebate clawback risk: brand manufacturer may reduce rebates when you switch

Multi-Year Adoption Forecasting

Our Biosimilar Adoption Modeling Engine identifies all brand biologic users eligible for biosimilar switch, models realistic adoption curves (phased over 12-24 months), accounts for physician resistance and rebate clawbacks, and generates implementation roadmaps with net savings.

Biosimilar Adoption Algorithm
// Identify eligible population
eligible_members = GET_members_on_biologics(
  brands: ["Humira", "Remicade", "Enbrel", "Neulasta", "Avastin"]
)

FOR each member IN eligible_members:
  biosimilar_available = CHECK_fda_approval(member.drug)
  clinically_appropriate = EVALUATE(
    diagnosis_codes,
    contraindications,
    physician_specialty
  )
  
  IF biosimilar_available AND clinically_appropriate:
    member.eligible = TRUE

// Model adoption curve (S-curve)
adoption_rate(month) = max_adoption / (1 + e^(-k×(month - inflection)))
  where:
    max_adoption = 75% (not 100% — clinical resistance)
    k = steepness factor (0.3 for aggressive, 0.15 for conservative)
    inflection = 9 months (when adoption hits 50%)

// Calculate savings
FOR month IN [1..36]:
  members_switched = eligible_count × adoption_rate(month)
  
  brand_cost = members_switched × brand_price × 12
  biosimilar_cost = members_switched × biosimilar_price × 12
  gross_savings = brand_cost - biosimilar_cost
  
  // Account for rebate clawback
  rebate_loss = brand_rebate_per_member × members_switched
  
  // Implementation costs
  implementation = prior_auth_setup + physician_education + 
                   patient_outreach + step_therapy_edits
  
  net_savings(month) = gross_savings - rebate_loss - implementation

cumulative_savings = SUM(net_savings over 36 months)

Engineering Architecture

Core Components

Eligibility Screener: Identify members on brand biologics with FDA-approved biosimilars
Adoption Curve: S-curve model with physician/patient resistance factors
Rebate Impact: Model brand rebate clawback when utilization drops
Implementation Planner: Generate formulary tier changes, PA edits, physician outreach

Adoption Metrics

Year 1 Adoption

25-35%

realistic uptake

Year 2 Adoption

55-70%

mature utilization

3-Year Savings

$1.2M-$4.5M

per 10K lives

ROI

12-18x

implementation cost

Real-World Applications

Humira Biosimilar Switch Program

•Population: 8,500 lives, 42 Humira users
•Brand cost: $6,845/month × 42 = $3.45M/year
•Biosimilar (Amjevita): $3,200/month × 42 = $1.61M/year
•Gross savings: $1.84M/year
•Year 1 adoption: 28% → actual savings $515K
•Year 2 adoption: 67% → actual savings $1.23M

Multi-Biosimilar Formulary Strategy

•Targeted: Humira, Remicade, Enbrel, Neulasta
•84 eligible members identified
•3-year cumulative savings: $2.7M
•Rebate clawback: -$340K (brand manufacturer penalty)
•Implementation cost: $180K (PA setup + education)
•Net savings over 3 years: $2.18M

Unlock Biosimilar Savings Now

See your eligible population. Model realistic adoption curves. Generate implementation plans with PA edits, physician outreach, and net savings projections.

Request Engine Demo→